STENTYS, a medical technology company commercializing the world's first and only Self-Apposing coronary stent, announces that it has received CE Marking for the longest version of its Xposition S Sirolimus-eluting self-apposing stent.
The Xposition stent portfolio already included three lengths (17 mm, 22 mm and 27 mm), and this 37 mm drug-eluting stent is particularly well-suited to the treatment of lesions in the left main coronary artery and in tapered vessels.
Segments longer than 25 mm have been demonstrated to have a higher degree of tapering (diameter difference of 0.5 mm or more) and to be an independent predictor of acute stent malapposition with conventional stents1.
Cardiologists now only need to implant a single self-apposing stent rather than a long conventional stent, thus minimizing the risk of malapposition and related complications.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: "We are very pleased to be able to offer cardiologists this new Self-Apposing drug eluting stent that is expected to increase our market share in the hospitals where we market our products."
STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease.
STENTYS’ Self-Apposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents.
The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents.